



For Immediate Release

**Leucadia Pharmaceuticals Launches Acetaminophen Injection**  
*FDA-Approved Generic to OFIRMEV® Acetaminophen Injection Expands Options for Treatment of Acute Pain*

CARLSBAD, Calif. – [Leucadia Pharmaceuticals](#), a U.S. leader in generic injectables and the commercial arm of [Custopharm, Inc.](#), today announced the launch of its latest generic, Acetaminophen Injection, 1000 mg/100 mL (10 mg/mL). The FDA-approved generic, which is now available, is therapeutically equivalent to OFIRMEV®<sup>1</sup> and is indicated for the management of mild to moderate pain, management of moderate to severe pain with adjunctive opioid analgesics and reduction of fever.

It is AP rated, bar coded, preservative free and does not contain natural rubber latex.

“The release of this latest generic injectable once again demonstrates Leucadia’s strategic focus on expanding access to safe, effective pharmaceuticals at substantially lower costs,” said Dr. William Larkins, Chief Executive Officer of Leucadia Pharmaceuticals. “Acetaminophen Injection is a widely proven therapy for the reduction of pain and fever and demand for expanded options in this market is extremely robust.”

Leucadia’s Acetaminophen Injection once again expands the drug manufacturer’s line of generic injectables approved by the Food and Drug Administration. Among the company’s recent additions are the first and only generic to the novel antineoplastic agent VALSTAR®<sup>2</sup> (valrubicin) Sterile Solution for Intravesical Instillation, the first and only FDA-approved Sodium Tetradecyl Sulfate (STS) Injection generic, used to treat small varicose veins of the lower legs and Icatibant Injection, an FDA-approved generic used to treat hereditary angioedema (HAE) attacks of the throat (laryngeal attack).

**About Leucadia Pharmaceuticals**

Leucadia Pharmaceuticals is a leader in the generic injectables market. We invest heavily in new product development while also pursuing partnerships and product acquisitions. Our goal is to provide important new generic injectable products to the acute and specialty markets and to reach communities and conditions that are under-served. Leucadia’s products include Acetaminophen Injection, Dihydroergotamine Mesylate Nasal Spray, Icatibant Injection, Sodium Tetradecyl Sulfate (STS) Injection, Valrubicin Intravesical Solution, USP, Dicyclomine HCl Injection, USP, Pentobarbital Sodium Injection, USP and Fludarabine Phosphate Injection, USP. Leucadia Pharmaceuticals was established in 2015 as the commercial arm of Custopharm, Inc. and is associated with Water Street Healthcare Partners. For more information, please visit [leucadiapharma.com](http://leucadiapharma.com).

**Contact**

Kara Eiseman  
Leucadia Pharmaceuticals  
844-538-2231  
[info@leucadiapharma.com](mailto:info@leucadiapharma.com)

---

<sup>1</sup> OFIRMEV® is a registered trademark of Mallinckrodt Pharmaceuticals.

<sup>2</sup> VALSTAR® is a registered trademark of Endo Pharmaceuticals.